NEW YORK – A team led by researchers at Memorial Sloan Kettering Cancer Center has uncovered clonal hematopoiesis patterns and genetic mutations that may contribute to the development of new tumors after cancer treatment, known as therapy-related myeloid neoplasms (tMNs).